Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX)
8.8400
+0.0800 (0.91%)
Amneal Pharmaceuticals is a leading pharmaceutical company focused on the development, manufacturing, and distribution of generic and specialty pharmaceuticals
The company offers a broad portfolio of high-quality, cost-effective medications across various therapeutic areas, including central nervous system disorders, infectious diseases, and pain management. Amneal is committed to improving access to essential medications through innovation in drug formulation and delivery. With a robust pipeline of products and a dedication to regulatory compliance, Amneal aims to meet the diverse needs of patients and healthcare providers while contributing to the overall efficiency of the healthcare system.
Pharmaceutical company Amneal Pharmaceuticals (NASDAQAMRX) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 18.4% year on year to $730.5 million. The company’s full-year revenue guidance of $3.05 billion at the midpoint came in 4.5% above analysts’ estimates. Its non-GAAP profit of $0.12 per share was 21.1% below analysts’ consensus estimates.
Amneal Pharmaceuticals' Q4 sales rose 18% to $730.52M, surpassing estimates, while adjusted EPS missed. The company forecasts up to $3.1B in 2025 revenue.
JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue forecast, with peak sales over $300 million.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Viatris (NASDAQVTRS).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Amneal (NASDAQAMRX).
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQAMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQANIP) and its peers.
Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 million, beating estimates. EPS hit $0.16, above consensus, driven by strong launches and specialty growth.
